ClinicalTrials.gg
RecruitingNCT07754409Updated Sep 2, 2026

Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.

An observational study in Non-Small Cell Carcinoma of Lung, sponsored by Göteborg University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Göteborg University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden — 24 open to participants now, 42 under way, 26 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sweden.

Started
2026
with 5 others
Observational
4 of 111
1 open now
Primary completion
2028-12
later than 29 of 41 live
Registered
110th of 111
by date

Among the 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden, this one is one of 6 that started in 2026, is one of 4 observational ones, reaches primary completion later than 29 of the 41 other live ones, and was the 110th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

24 of the 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden, or all of them as a file.
02

Study summary

Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall survival and progression-free survival. Patients with lung cancer have a high burden of distressful symptoms at diagnosis and during chemoradiotherapy. Side-effects from immunotherapy differs, they are unspecific and may develop at any point during treatment. However, it is not investigated thoroughly during adjuvant treatment in locally advanced lung cancer. As new oncological treatments are being introduced, focus must be placed on patients quality of life and how patients endure treatment to be able to know how to best support patients during this treatment. The knowledge gained from this project include how adjuvant immunotherapy treatment impacts health. This knowledge is sparse due to the novelty of the treatment.

03

Conditions studied

  • Non-Small Cell Carcinoma of Lung

Keywords

  • non-small lung cancer
  • quality of life
  • self-reported health
  • immunotherapy
  • oncological treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients cared for at a specialized oncology centre in Västra Götaland, Sweden and at a regional hospital in Jönköping region in Sweden.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with locally advanced non-small lung cancer
  • cared for at either one of two specialized oncology centres
  • ≥ 18 years of age
  • planned for concurrent chemoradiotherapy including ICI for 12 months
  • performance status 0-2.

Exclusion criteria

Exclusion Criteria:

  • diseases or comorbidities that may have significant impact on the outcome variables
  • limited understanding of the Swedish language preventing the possibility to give oral and written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with locally advanced lung cancer cared for at two specialized oncology centres.

    Inclusion criteria: locally advanced lung cancer, ≥ 18 years of age, planned for concurrent chemoradiotherapy including ICI for 12 months and performance status 0-2.

06

What researchers measure

Primary outcomes

  1. Changes in aspects of Quality of life (totalscore and subscale scores) during oncological treatment measured with the questionnaire EORTC QLQ C30.

    Changes between baseline and 12 months after start of immunotherapy will be assessed with the European Organisation for Research and Treatment of Cancer Quality of life scale (EORTC QLQ-C30). The 30 item instrument measure quality of life in patients with cancer. Scores range from 0-100 where a higher score represents higher quality of life.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

Secondary outcomes

  1. Changes in self-reported health during oncological treatment measured with EQ-VAS.

    Changes in general health will be assessed with EQ-VAS which is a visual analogue scale, measuring a persons overall health-related quality of life. The scale ranges from 100 (the best health you can imagine) to 0 (the worst health you can imagine').

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

  2. Changes in Quality of life specifically in patients with lung cancer during oncological treatment measured with the questionnaire EORTC QLQ - LC13.

    A lung cancer module to assess quality of life when having a lung cancer. The European Organisation for Research and Treatment of Cancer Quality of life in lung cancer scale EORTC QLQ - LC13 comprise 13 items, scores range from 0-100 where a higher score represents better quality of life.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

  3. Changes in well-being related to immune checkpoint modulators during oncological treatment measured with the questionnaire FACT-ICM.

    Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator (FACT ICM) comprise 52 items (5 point Likert-type response alternatives between 0 not at all -4 very much). Higher scores indicates better well-being.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

  4. Changes in existensial health during oncological treatment measured with the questionnaire FACIT-Sp-12.

    Functional Assessment of Chronic Illness Therapy -Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) measures perceived existensial health with a 5 point Likert-type scale (0 not at all - 4 very much), higher score indicates better perceived existensial health.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

  5. Changes in health promoting factors during oncological treatment assessed with SOC-13.

    Sense of coherence scale (SOC-13) is a 13- item scale comprised of three components: Comprehensibility, Manageability and Meaningfulness.It aims to measure how persons cope with stressfull situations as for example cancer. Scores 13-91 where higher scores indicate better coping strategies.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

Other outcomes

  1. Changes in health promoting factors during oncological treatment assessed with SEMCD-4.

    A person's self-efficacy asessed with Self-Efficacy to Manage Chronic Disease (SEMCD) Scale. With the SEMCD the patient rate confidence related to four tasks on a 1 to 10 scale (1 not at all confident" and 10 totally confident). A higher score indicates better self-efficay.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

  2. Perceived quality of care during onocological treatment measued with GPCCQ 1.0 Scale.

    The Generic Person-centred Care Questionnaire (GPCCQ) assess patients experiences of Personcentredness in Care. Totally 18 items assess perceived personcentredness on a likert scale from 1 not at all to 5 completely. A higher score indicates higher personcentredness.

    Time frame: From enrollment before oncological treatment up til 18 months after start of treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 27 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Aug 10, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07754409
Collaborators
Västra Götalandsregionen, Region Jönköping County
Responsible party
Sofie Jakobsson (Associated professor, Göteborg University) — Principal investigator
First posted
Aug 10, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 2, 2026

Study contacts

Sofie Jakobsson, Associated professor
Contact
sofie.jakobsson@fhs.gu.se
+46766182858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion